The Why and How of SGLT2 Inhibitors in CKD A Practical Approach

Main Article Content

Megan Borkum
Adeera Levin

Keywords

SGLT2 inhibitor, chronic kidney disease, cardioprotective, euglycemic dka

Abstract

Abstract
There is growing evidence for the cardiorenal protective benefits of sodium-glucose co-transport 2 (SGLT2) inhibitors for diabetic and non-diabetic-related chronic kidney disease (CKD) patients. As many clinical guidelines increasingly incorporate SGLT2 inhibitors, we sought to review: the rationale and background for their use in CKD, monitoring after initiation, how to handle concomitant diuretics and diabetic medication, therapeutic role and side effects, preventing adverse events, and the use of SGLT2 inhibitors with other novel agents for slowing the trajectory kidney function decline. We hope to overcome prescriber hesitancy and uncertainty through a case-based discussion and increase prescription rates in appropriate patients to benefit more from this therapy.


Résumé
Il existe de plus en plus de données probantes à l’appui des avantages liés à la protection cardiorénale des inhibiteurs du cotransporteur sodium-glucose de type  2 (SGLT2) chez les patients atteints d’insuffisance rénale chronique (IRC) liée ou non au diabète. Comme de nombreuses lignes directrices cliniques intègrent de plus en plus les inhibiteurs du SGLT2, nous avons cherché à faire le point sur : la justification et le con-texte de leur utilisation en IRC, la surveillance après l’amorce du traitement, la façon de gérer la prise con-comitante de diurétiques et de médicaments contre le diabète, le rôle thérapeutique et les effets secondaires, la prévention des évènements indésirables et l’utilisation des inhibiteurs du SGLT2 avec d’autres nouveaux agents pour ralentir la trajectoire du déclin de la fonction rénale. Par l’intermédiaire d’une analyse fondée sur des cas concrets, nous espérons surmonter les réticences et l’incertitude des prescripteurs et augmenter le taux de prescription pour les patients chez qui le traitement est approprié de sorte que davantage de patients puissent tirer profit de ce traitement.

Abstract 40 | PDF Downloads 43 XML Downloads 11 HTML Downloads 10

References

1. Cherney DZ, Kanbay M, Lovshin JA. Renal physiology of glucose handling and therapeutic implications. Nephrol Dialysis Transplantat. 2020 Jan 1;35(Supplement_1):i3–12.
2. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853–62.
3. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Ann Intern Med. 2013 Aug 20;159(4):262–74.
4. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Invest. 2014 May;5(3):265–75.
5. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295–306.
6. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436–46.
7. Heerspink HJL, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016 Jun;18(6):590–7.
8. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2017 Aug;5(8):610–21.
9. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. American Journal of Kidney Diseases. 2020 Jan;75(1):84–104.
10. Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports. 2022 May;S2468024922013729.
11. Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al. Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis. JAHA. 2017 May 5;6(5):e005686.
12. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018 Oct;61(10):2098–107.
13. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016 Aug;18(8):783–94.
14. Petrykiv S, Sjöström CD, Greasley PJ, Xu J, Persson F, Heerspink HJL. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. CJASN. 2017 May 8;12(5):751–9.
15. Granata A, Pesce F, Iacoviello M, Anzaldi M, Amico F, Catalano M, et al. SGLT2 Inhibitors: A broad impact therapeutic option for the nephrologist. Front Nephrol. 2022 Apr 29;2:867075.
16. van Raalte DH, Cherney DZI. Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials. Kidney International. 2018 Sep;94(3):459–62.
17. Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018 Aug 9;3(15):e98720.
18. de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2020 Oct;98(4):S1–115.
19. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14;385(16):1451–61.
20. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28.
21. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644–57.
22. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347–57.
23. Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International. 2021 Jul;100(1):215–24.
24. Pitt B, Bhatt DL. Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes? Circulation. 2021 Jul 6;144(1):4–6.
25. Abrahami D, D’Andrea E, Paik JM, et al. 1086-P: Cardiovascular effectiveness of SGLT2 inhibitors: head-to-head comparisons. Diabetes. 2022 Jun 1;71(Supplement_1):1086-P.
26. Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovasc Diabetol. 2022 Dec;21(1):67.
27. Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: The RECEDE-CHF Trial. Circulation. 2020 Nov 3;142(18):1713–24.
28. Lam D, Shaikh A. Real-Life Prescribing of SGLT2 Inhibitors: How to handle the other medications, including glucose-lowering drugs and diuretics. Kidney360. 2021 Apr 29;2(4):742–6.
29. Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL, Kalyani RR, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes. J Am Coll Cardiol. 2020 Sep;76(9):1117–45.
30. Heerspink HJL, Cherney DZI. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. CJASN. 2021 Aug;16(8):1278–80.
31. Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International. 2021 Apr;99(4):999–1009.
32. Rampersad C, Kraut E, Whitlock RH, Komenda P, Woo V, Rigatto C, et al. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study. Am J Kidney Dis. 2020 Oct;76(4):471-479.e1.
33. Zhao M, Sun S, Huang Z, Wang T, Tang H. Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. CJASN. 2021 Jan 7;16(1):70–8.
34. Iskander C, Cherney DZ, Clemens KK, Dixon SN, Harel Z, Jeyakumar N, et al. Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ. 2020 Apr 6;192(14):E351–60.
35. Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, et al. Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney International. 2019 Aug;96(2):489–504.
36. Patel N, Hindi J, Farouk SS. Sodium-Glucose Cotransporter 2 Inhibitors and kidney transplantation: what are we waiting for? Kidney360. 2021 Jul 29;2(7):1174–8.
37. Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the benefits of SGLT2 inhibitors for type 1 diabetes. Diabetes Ther. 2020 Jan;11(1):37–52.
38. Ata F, Yousaf Z, Khan AA, Razok A, Akram J, Ali EAH, et al. SGLT2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021 Dec;11(1):10293.
39. Bartolo C, Hall V, Friedman ND, Lanyon C, Fuller A, Morrissey CO, et al. Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports. BMC Infect Dis. 2021 Dec;21(1):284.
40. Mende CW. Chronic Kidney disease and SGLT2 inhibitors: A review of the evolving treatment landscape. Adv Ther. 2022 Jan;39(1):148–64.
41. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 Dec 3;383(23):2219–29.
42. Provenzano M, Puchades MJ, Garofalo C, Jongs N, D’Marco L, Andreucci M, et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial. JASN. 2022 Apr 19;ASN.2022020207.
43. Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. JASN. 2021 Sep;32(9):2352–61.
44. Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. European Heart Journal. 2020 Sep 21;41(36):3421–32.
45. Juni RP, Al-Shama R, Kuster DWD, van der Velden J, Hamer HM, Vervloet MG, et al. Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction. Kidney International. 2021 May;99(5):1088–101.
46. Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018 Mar;61(3):722–6.